Update on the current modalities used to screen high risk youth for prediabetes and/or type 2 diabetes mellitus

Preneet Cheema Brar

doi:10.6065/apem.2019.24.2.71

Ann Pediatr Endocrinol Metab > Volume 24(2); 2019 > Article

Brar: Update on the current modalities used to screen high risk youth for prediabetes and/or type 2 diabetes mellitus

Review Article

Annals of Pediatric Endocrinology & Metabolism 2019;24(2): 71-77.

Published online: June 30, 2019

DOI: https://doi.org/10.6065/apem.2019.24.2.71

Update on the current modalities used to screen high risk youth for prediabetes and/or type 2 diabetes mellitus

Preneet Cheema Brar, MD

Division of Pediatric Endocrinology and Diabetes, New York University School of Medicine, New York, NY, USA

Address for correspondence: Preneet Cheema Brar, MD Division of Pediatric Endocrinology and Diabetes, New York University School of Medicine, 135 E 31st Street, Second Floor, New York, NY 10016, USA
Tel: +1-212-263-5940 Fax: +82-212-263-9696 E-mail: preneet.brar@nyumc.org

Received March 31, 2019 Revised June 3, 2019 Accepted June 11, 2019

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The modalities currently employed to screen for type 2 diabetes mellitus (T2DM)/prediabetes are HbA1_c, fasting plasma glucose (FPG), and 2-hour plasma glucose (PG) during an oral glucose tolerance test (OGTT). The purpose of this review is to highlight the positive qualities and pitfalls of these diagnostic modalities and reflect on the most reasonable and effective approach to screen high risk youth. Given its inherent preanalytical advantages, glycated hemoglobin (HbA1_c) continues to be the preferred diagnostic modality used by pediatricians to screen high risk youth. However, when the three aforementioned tests are performed in youths of different races/ethnicities, discrepant results for T2DM/prediabetes are observed. The prevalence rates for T2DM vary from 0.53% in Chinese youth (including youth of all body mass indexes) to 18.3% in high-risk, overweight, obese Korean youth. Moreover, the FPG is abnormal (>100 less than <126 mg/dL) in 15% of Korean youth versus 8.7% of Chinese youth. The prevalence rates for prediabetes are 1.49% in Chinese youth versus 21% in Emirati youth (HbA1_c, 5.7%–6.4%). The coefficient of agreement, k, between these screening tests for T2DM are fair, 0.45–0.5 across all youth. However, using HbA1_c as a comparator, the agreement is weak with FPG (k=0.18 in German youth versus k=0.396 in Korean youth). The American Diabetes Association (ADA) Standards of Medical Care Guidelines define “high risk youth” who need to be tested for T2DM and/or prediabetes. OGTT and HbA1_c do not always detect T2DM in similar individuals. HbA1_c may not be an ideal test for screening Hispanic and African American youth. FPG and OGTT are suitable screening tests for youth of ethnic minorities and those with cystic fibrosis or hemoglobinopathies. Performing all three tests either together or sequentially may be the only way to encompass all youth who have aberrations in different aspects of glucose homeostasis.

Keywords: Type 2 diabetes mellitus, Prediabetic state, Glycated hemoglobin A, Fasting plasma glucose, Oral glucose tolerance test, Youth, Screening tests

Introduction

Prediabetes, a condition in which the glucose levels are not high enough to meet the criteria of diabetes but also cannot be considered normal, is an intermediate state along the spectrum of glucose homeostasis.

Table 1 defines type 2 and prediabetes as per the Standard of Medical Care in Diabetes update in 2019 [1]. In 2010, the ADA added glycated hemoglobin (HbA1c) of ≥6.5% as diagnostic criteria for type 2 diabetes mellitus (T2DM) and made HbA1c of 5.7%–6.4% (39–47 mmol/mol) as the criteria for prediabetes [1]. The risk for developing diabetes is a continuum and spans from low below the cut-off values to disproportionately higher at the upper end of this range.

Prevalence of type 2/prediabetes in youth

The obesity epidemic has led to an exponential increase in prediabetes and/or mellitus (T2DM, and this rise has been the most dramatic in Hispanic, American-Indian and African-Americans populations [2,3]. Thirty years ago, T2DM in youth was considered rare; the first cases of T2DM were reported in the mid-1990s [4]. However, the last decade has seen a dramatic increase in the numbers of youth with T2DM, especially in racial and ethnic minorities [2], and projections suggest that there will be 1,000,000 youths with T2DM in the United States by the year 2050 [5].

The prevalence rates for prediabetes in youth are highly variable and range from 18%–28% in obese youth [6]. The conversion rate of prediabetes to T2DM is accelerated in youth, with studies showing a 15% annual reduction in beta-cell function with a mean transition time from prediabetes to diabetes of 2.5 years more so than in adults [7]. Therefore, in high risk youth with prediabetes, screening, diagnosis, and therapeutic lifestyle counselling are paramount for diabetes prevention.

Table 2 defines the risk-based screening criteria in order to provide guidance to pediatricians for initial and follow-up diabetes screening in high risk youth [8]. The value of the diagnostic tools approved by the ADA have been adopted to help identify asymptomatic youth at an increased risk for T2DM and/or prediabetes.

FPG and 2-hour PG as diagnostic tools

Historically, the diagnostic thresholds for impaired fasting glucose (IFG) and 2-hour plasma glucose (PG) were established from epidemiologic studies in adults, which found that the diabetes-related complication of retinopathy was prevalent and increased exponentially above the fasting PG cut off of 126 mg/dL and the 2-hour PG cutoff of 200 mg/dL, thus defining these thresholds [9]. The World Health Organization defines IFG as 110 mg/dL (6.1 mmol/L).

The oral glucose tolerance test (OGTT) diagnostic criteria have been considered the "gold standard" since their inception in 1997. Fasting plasma glucose (FPG) and 2-hour PG cut off values have not been validated in youth, and studies to do so are unlikely.

Benefits and pitfalls of FPG and 2-hour OGTT

The OGTT provides an overview of different aspects of beta cell function (fasting and prandial) within the background of insulin resistance, which is present in most obese youth. Moreover, it can illustrate whether there is more hepatic insulin resistance (higher FPG) versus postprandial resistance (higher 2-hour PG).

The main disadvantages of the OGTT are as follows: (1) the requirement for an overnight fast of at least 8 hours, which could be a challenge for young children; (2) difficulty in staffing pediatric offices to conduct the OGTT during office hours; (3) the length of the test (2 hours) can be a deterrent for both families and physicians; and (4) Some pediatricians do not feel comfortable ordering or interpreting OGTT results. The major caveat of OGTT in pediatrics is that it has poor reproducibility, and there have been no validation studies in youth [10]. A study at Yale in youths with prediabetes who were followed with serial OGTTs revealed that 50% of youths with prediabetes reverted to normal glucose tolerance, whereas 24% progressed from prediabetes to diabetes [11].

Below an HbA1c level of 7%, 2-hour PG reflects prandial hyperglycemia increases before increases of FPG, whereas in patients with an HbA1c level above 8%, the contribution of basal hyperglycemia to overall hyperglycemia becomes predominant. So, youth with impaired glucose tolerance may have near-normal HbA1c, and these youth will be missed if only FPG is done without an OGTT.

Although FPG requires fasting, its advantage is that it requires only one blood draw. FPG is affected by stress/illness and drops by 5%–7% per hour in a sample due to glycolysis. Both FPG and OGTT have intra-individual variability, which is much higher for OGTT at 12.7% versus 5.7%–8.3% for FPG [12].

HbA1_c as a diagnostic tool

The HbA1_c test was used in prospective studies in adults, and it was found to have a consistent linear association with the development of diabetes. Systematic reviews of over 40,000 adults from 16 studies have shown that the 5-year risk for developing diabetes was 9%–25% when HbA1_c was ≥5.7%, and this risk increased to 25%–50% for HbA1_c ≥6%–6.5% [13]. This data formed the ADA’s basis in using HbA1_c as screening criteria for T2DM/prediabetes in 2010. Since the acceptance of HbA1_c as a screening tool, there has been a tremendous appeal among pediatricians to evaluate HbA1_cs.

1. Benefits and pitfalls of HbA1_c

HbA1_c is not a direct measure of glycemia. It is an indirect measure, and it represents the amount of hemoglobin with glucose attached to the N-terminal valine of the beta chain, thus reflecting blood glucose levels over the previous 2–3 months (based on red blood cell turnover). HbA1_c must be performed using a method that is certified by the National Glycohemoglobin Standardization Program (www.ngsp.org). The major advantages for HbA1_c are that it does not require fasting, it has less pre-analytical and glycemic variability, and it is not affected by stress or illness. However, HbA1_c has lower sensitivity and a higher cost, and it is availability is limited in many developing countries.

2. Nonglycemic factors that affect HbA1_c levels in youth

(1) Red blood cell (RBC) turnover: Lower HbA1_c values are observed in conditions of high RBC turnover, such as cystic fibrosis [14], hemorrhage, and hemolysis, and higher HbA1_c values are seen when RBC turnover is slowed down, as in spherocytosis and iron deficiency anemia [15].

(2) Medications: Retroviral drugs [16], dapsone, hydroxyurea, and vitamins C & E can falsely lower HbA1_c, and aspirin can interfere with the laboratory assay and artificially raise the HbA1_c value [16].

3. Hemoglobinopathies

Hemoglobin variants, such S, C, D, and E, are substitutions for the B chain and can interfere with certain assays. More information about hemoglobinopathies is available at ngsp.org. African American youth who are heterozygous for the S trait could have an average HbA1_c which is 0.3% higher for any given glucose level [17]. When corrected for age, body mass index (BMI), sex, and blood pressure, the HbA1_c levels in African Americans is higher compared to Caucasians, which could be the result of inherent differences in glycation triggers besides the racial differences in the presence of traits [17].

4. Age

There is an age-related linear increase in HbA1_c values for the same levels of glycemia, suggesting more efficient glycation in youth compared to adults [18].

Is HbA1_c the ideal test?

After HbA1_c came to the forefront as a screening test in 2010, several pediatric studies reported the validity of the HbA1_c.

Nowicka et al. [19] compared HbA1_c to the gold standard OGTT in over 1,000 patients. Of the 347 obese youth with prediabetes on the OGTT, 240 subjects had an HbA1_c below the cutoff value of 5.7%. This study highlighted the unacceptably low sensitivity of HbA1_c as a screening test. Brar et al. [6] studied 149 obese youth who were referred for HbA1_c values ≥ 5.7% who then underwent an OGTT. At a sensitivity of 75% and a specificity of 57%, HbA1_c has been unreliable due to its high false positive rate.

Buse et al. [20] studied 3,980 sixth-grade youth and found that HbA1_c and IFG as screening tools defined different ethnic/racial groups. Elevated HbA1_c was associated with the Hispanic and Black races, strong family history of diabetes, higher BMIs, higher waist circumferences and higher insulin values. High risk HbA1_c was seen in 128 subjects (3.2%), and abnormal FPG was observed in 635 subjects (16%). IFG was found in youth who were mostly Hispanic, it being fivefold more common when compared to HbA1_c in these children. The authors, among others, proposed that these contradictions call into question the utility of HbA1_c as a standalone screening test. The conversion rate to diabetes was 0.8% for HbA1_c and 1.1% for FPG in a 2-year follow-up evaluation.

Several studies indicate that using adult cutoff points for HbA1_c to predict T2DM/prediabetes significantly underestimates the prevalence of these conditions in the pediatric and adolescent population, and consequently, a lower HbA1_c cutoff point has to be proposed for children [19,21].

How do these tests do when compared to each other?

A retrospective review of 72 papers analyzed the comparisons of these three tests in youth. Table 3 highlights the findings of 5 papers.

Using FPG and HbA1_c, Yang et al. [22] studied the prevalence of T2DM and/or prediabetes in 7,519 Chinese youth in grades 1, 7 and 10 in Shenzhen province. The cross-sectional study found a T2DM prevalence rate of 0.53% (n=4). Additionally, the prevalence of an abnormal FPG prevalence was 7 fold higher than the prevalence of an abnormal HbA1_c (8.72% vs. 1.49%), and the odds ratio for an abnormal result for either test was higher for boys than girls (odds ratio, 1.21). As the authors did the testing on all youth irrespective of BMI, they found an interesting U-shaped curve, indicating higher rates of T2DM/prediabetes for underweight and obese youth. The proportion of prediabetes was higher for males than females, and the proportion decreased with grade for males but increased for females.

Al Amiri et al. [23] studied youth from 16 schools across the United Arab Emirates, a country with one of the highest prevalences of diabetes in the world. Of the 1,434 youth who were screened, 433 were overweight or obese. Among these 1,034 youth, 0.87% had T2DM. A significantly higher proportion of children had prediabetes using the results from the HbA1_c criteria rather than the OGTT criteria (21.9 % vs. 5.4%). HbA1_c results were discrepant for prediabetes but not for T2DM.

Nam et al. [24] simultaneously performed OGTT and HbA1_c in 384 high risk overweight and obese youth across 6 hospitals in South Korea. The overall prevalence of T2DM and prediabetes was 18% and 31.1%, respectively. The authors proposed that HbA1_c of 6.2% had a sensitivity of 91.5% and specificity of 93.7% with an area under the curve (AUC) of 0.972. For prediabetes 5.8 had a statistical significance with an AUC=0.795 (95% confidence interval [CI], 0.750–0.840), with a sensitivity of 64.1% and a specificity of 83.8% to screen for prediabetes. The authors found that 49 of the youths with T2DM fulfilled all three diagnostic criteria, and five youth fulfilled the OGTT criteria for T2DM but no the ADA’s HbA1_c criteria of 6.5%. The authors demonstrated that the kappa coefficient of agreement between the two tests could be interpreted as fair (0.21–0.40) to moderate (0.41–0.60). For prediabetes, 9.4% of the youth fulfilled all the criteria, and 16.1% of the subjects would have missed without an OGTT as they only had an abnormal 2-hour PG. Because the pediatric cut-off value for HbA1_c across racial/ethnic groups remains obscure, the authors recommended the combination of fasting and 2-hour glucose levels, in addition to HbA1_c, as the best modality to screen for T2DM and/or prediabetes at this time.

Khokhar et al. [25] studied predominantly African American and Caribbean youth (n=230) and found that HbA1_c had a receiver operating curve of 0.64 (95% CI, 0.56–0.72), showing that HbA1_c had poor sensitivity for detecting prediabetes when compared to OGTT. While 56% of the cohort had an elevated HbA1_c, 26% had an abnormal OGTT result, with 18% testing positive for both HbA1_c and OGTT. All tests were done within a 3-month period. The authors proposed that HbA1_c when combined with BMI z-score and homeostatic model of insulin resistance in a regression model was a better predictor of prediabetes in youth.

Ehehalt et al. [26] studied a large cohort of German youth (n=4,848) from several hospitals across Germany. The prevalence of T2DM was 0.02% (n=115), and these youth met one of the ADA criteria for T2DM. For those with T2DM, the OGTT had a sensitivity of 44.0% (95% CI, 30.0–58.7) and a specificity of 99.6% (95% CI, 99.3–99.7), whereas HbA1_c had a sensitivity of 84.0% (95% CI, 70.9–92.8) and a specificity of 99.3% (95% CI, 99.0–99.5). The results were discordant for those whose 2-hour glucose levels were ≥200 mg/dL diabetes, median FPG, and median HbA1_c levels were 110 mg/dL and 6.3 % (prediabetes) range. There was a high correlation (r=0.73) between FPG and 2-hour PG in those with confirmed T2DM (n=50) on repeat testing with either an OGTT and/or HbA1_c. Prediabetes was highest with HbA1_c criteria at 23% vs. FPG 12% vs. 2-hour PG 8%. In those youth with an abnormal HbA1_c, the correlation between HbA1_c and FPG was weak at r=0.18. However, the authors compared FPG+2-hour-PG (OGTT) vs. glycated hemoglobin and found an improvement in correlation with HbA1_c (%) (log-transformed data, r=0.21, n=4,848, P<0.001). The authors surmise that these weak correlations were much lower than those reported in adults, possibly due to the fact that the tests measure different disorders of glucose metabolism. Moreover, the reproducibility of OGTT continues to be an area of controversy [26].

What are the inadequacies of the current diagnostic criteria for T2DM and/or prediabetes?

(1) The screening tests results are discrepant according to the ethnicity/race of the youth, so the "one size fits all" examination cannot be used for youth from different parts of the world.

(2) HbA1_c as a standalone screening test for T2DM and/or prediabetes can result in the overdiagnosis of prediabetes, and many youths will have to undergo unnecessary OGTTs. The relevant literature contradicts the call for lowering HbA1_c cut-off values for youth, as suggested by several studies. Youths with a high HbA1_c above 6.2% must have an OGTT to establish the diagnosis of T2DM [27].

(3) Patients with a significant elevation of HbA1_c ≥ 5.8%–6% or higher and normal OGTT results are at a higher risk for developing diabetes. The poor reproducibility of the OGTT in these situations may warrant testing HbA1_c levels at three-month intervals, especially if the patient’s BMI is increasing.

(4) Although OGTT is not an "ideal test," it is the only test clinicians can use to assess prandial hyperglycemia. Youths with near-normal HbA1_c values who have IGT will be missed if only FPG is tested.

Are there any alternatives to the current screening tests?

(1) Short-term markers of glycemia, such as 1,5-anhydroglucitol, glycated albumin and fructosamine, reflect glycemia ranging from 48 hours to 4 weeks, and they are promising for diabetes more so than for prediabetes screening [28]. Chan et al. [29] studied these markers in 14.3-year-old high risk youth (n=56) who were on a continuous glucose monitor. These markers predicted the glycemic variability as reported by the continuous glucose monitoring data independent of HbA1_c.

(2) A 1-hour PG value of 155 mg/dL (8.6 mmol/L) has been assessed for identifying prediabetes in adults [30]. Jagannathan et al. [31] studied 212 adults and found the k coefficient of agreement for one-hour PG was 2 fold higher than HbA1_c for prediabetes. Abdul-Ghani found that the receiver operating characteristic (ROC) curve for 1-hour PG was much higher than the HbA1_c ROC curve for prediabetes (r=0.84 vs. 0.73) [32]. Kasturi et al. [33] studied the reproducibility and predictive value of 1-hour PG compared to the standard OGTT. Nondiabetic adolescent girls with obesity underwent a multiple-sample OGTT at baseline (n=93), 6 weeks (n=83), and 1 year (n=72). The shorter 1-hour OGTT provided the diagnostic equivalent of the standard OGTT with the advantage of being a shorter risk assessment.

Conclusions

HbA1_c, FPG, and 2-hour PG provide a dynamic overview of different aspects of glucose homeostasis, although the results from these tests are often discrepant based on the race/ethnicity of the youth in which they are performed. Of note, when done together they can perform below their diagnostic threshold for prediabetes in 25% of youth for up to 2 years preceding the diagnosis of diabetes.

Risk-based screening for T2DM and/or prediabetes should be considered in youth at the onset of puberty or ≥10 years of age in overweight and obese youth who have 2 additional risk factors (Table 2). In high risk ethnic groups, such as African Americans and Hispanic youth, a FPG and/or OGTT may be more suitable than HbA1_c. Based on our current literature review to date, there is limited data to support using HbA1_c as a standalone screening test for high risk youth. As the pediatric cut-off values for HbA1_c across racial/ethnic groups remain unclear, it is appropriate to recommend the combination of fasting and 2-hour glucose levels, in addition to HbA1_c, as the best way to screen for T2DM and/or prediabetes at this time.

Notes

Conflict of interest No potential conflict of interest relevant to this article was reported.

Table 1.

Categories of increased risk for diabetes (prediabetes)^*

FPG 100 mg/dL (5.6 mmol/L) to 125 mg/dL (6.9 mmol/L) (IFG)

2-hr PG during 75-g OGTT 140 mg/dL (7.8 mmol/L) to 199 mg/dL (11.0 mmol/L) (IGT)

A1c 5.7%–6.4% (39–47 mmol/mol)

FPG, fasting plasma glucose; PG, plasma glucose; IFG, impaired fasting glucose; OGTT, oral glucose tolerance test; IGT, impaired glucose tolerance.

^* For all 3 tests, risk is continuous, extending below the lower limit of the range and becoming disproportionately greater at the higher end of the range.

Adapted from American Diabetes Association. Diabetes Care 2019;42(Suppl 1):S13-28.[1]

Table 2.

Risk-based screening for type 2 diabetes or prediabetes in asymptomatic children and adolescents in a clinical setting^*

Plus one or more additional risk factors based on the strength of their association with diabetes as indicated by evidence grades:

• Maternal history of diabetes or gestational diabetes mellitus during the child's gestation

• Family history of type 2 diabetes in first- or second-degree relative

• Race/ethnicity (Native American, African American, Latino, Asian American, Pacific Islander)

• Signs of insulin resistance or conditions associated with insulin resistance (acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational-age birth weight)

Criteria: overweight (body mass index>85th percentile for age and sex, weight for height >85th percentile, or weight >120% of ideal for height)

^* Age less than 18 years.

Adapted from Arslanian S, et al. Diabetes Care 2018;41:2648-68.[8]

Table 3.

Demographic data and screening tests for prediabetes in five relevant studies

Author	Average HbA1_c^ll	Race	Age (yr)	Weight^*	Male sex (%)	BMI z-score	FBG	HbA1_c	OGTT	Combined (FPG+ HbA1_c+ 2-hr PG	K-coefficient of agreement	Notes
Yang et al. [22]	7,519	Chinese	6–17	5823-N/896-OW/437- OB	55		8.72%† (CI, 8–9.36)	1.49%† (CI, 1.22–1.77)	Not done	9.8% CI† (9.13–10.47)		Higher rates males vs. females
												†FPG=1.9 vs. 0.9; P=0.001
												†HbA1_c=9.1 vs. 8.3; P=0.2
Al Amiri et al. [23]	1,034	United Arab Emirates	14.7	228-OW/806-OB	58	2.1 (1.8–2.4)	NA	12.1%†	NA	5.4%†		Concordance between HbA1_c and FPG=11%
Nam et al. [24]	389	Korean	13+2.5	48-OW/314-OB	55	2.3+0.6	15%† (n=61)		20%† (n=81)	31.1%† (n=121)	k^‡=0.464 CI (0.4–0.5) FPG+2 hr	9.4% fulfilled all criteria-FPG+HbA1_c+2-hr PG
									2-hr PG=7.9+1 mmol/L		k=0.396 (0.356–0.46) FPG	11% would have missed Without OGTT
									2-hr PG=7.9+1 mmol/L		k=0.47(0.46–0.500) 2-hr PG	11% would have missed Without OGTT
Khokhar et al. [25]	230	Caribbean/African-American (83% of cohort)	13.5+2.8	230-OW/OB	43	2.30+0.40	91+13.6 mg/dL	56%† (n=129); HbA1_c=5.7%±0.5%	25%† (n=60)	18%† (n=42) had prediabetes
Khokhar et al. [25]	230	Caribbean/African-American (83% of cohort)	13.5+2.8	230-OW/OB	43	2.30+0.40	91+13.6 mg/dL	56%† (n=129); HbA1_c=5.7%±0.5%	2-hr PG=113±30 mg/dL	18%† (n=42) had prediabetes
Ehehalt et al. [26]	4,848	German	13+2.4	759-OW/4090- OB	45	2.8 0.6		9%† (n=436); 103 mg/dL; IQR, 101–103	23%† (n=1,143); 5.8% (IQR, 5.7%–6%)	12%† (n=599); 149 mg/dL; IQR, 144–161)	k^§=0.18 for FPG	1-Point increase in HbA1_c=2.5-4 mg/dL ↑ in FPG=6-9 mg/dL ↑ in 2-hr PG
											k=0.17 for 2-hr PG
											K=0.21 FPG+2-hr PG

FPG=(ADA criteria=5.6–6.9 mmol/L or >100 mg/dL or less <126 mg/dL); HbA1_c=5.7% to 6.4% (38.8 to 46.5 mmol/mol); (2-hr plasma glucose [PG] challenge)=7.8–11.0 mmol/L or >140 but <200 mgl/dL.

FPG, fasting plasma glucose; ADA, American Diabetes Association; HbA1_c, glycosylated hemoglobin; IQR, interquartile range; BMI, body mass index; CI, confidence interval; OW, overweight; OB, obese; NA, normal; IFG, impaired fasting glucose; OGTT, oral glucose tolerance test; IGT, impaired glucose tolerance.

^* Normal N/overweight-OW/obese-OB. †Prevalence rate for prediabetes in the studies.

^‡ k coefficient was used HbA1_c as comparator.

^§ k coefficient used HbA1_c as comparator but all values were log transformed.

^ll Average HbA1_c in the prediabetes grp=5.8+ 0.8. HbA1_c of 5.8% had a sensitivity of 64% and specificity of 84% with area under the curve of 0.795.

Conversion to SI units: A1c (mmol/mol)=10.93×A1c (%)–23.95.

References

1. American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019;42(Suppl 1):S13–28.

2. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. JAMA 2014;311:1778–86.

3. Dabelea D, Pettitt DJ, Jones KL, Arslanian SA. Type 2 diabetes mellitus in minority children and adolescents. An emerging problem. Endocrinol Metab Clin North Am 1999;28:709–29.

4. Libman I, Arslanian SA. Type II diabetes mellitus: no longer just adults. Pediatr Ann 1999;28:589–93.

5. Imperatore G, Boyle JP, Thompson TJ, Case D, Dabelea D, Hamman RF, et al. Projections of type 1 and type 2 diabetes burden in the U.S. population aged <20 years through 2050: dynamic modeling of incidence, mortality, and population growth. Diabetes Care 2012;35:2515–20.

6. Brar PC, Mengwall L, Franklin BH, Fierman AH. Screening obese children and adolescents for prediabetes and/or type 2 diabetes in pediatric practices: a validation study. Clin Pediatr (Phila) 2014;53:771–6.

7. Weiss R. Impaired glucose tolerance and risk factors for progression to type 2 diabetes in youth. Pediatr Diabetes 2007;8 Suppl 9:70–5.

8. Arslanian S, Bacha F, Grey M, Marcus MD, White NH, Zeitler P. Evaluation and management of youth-onset type 2 diabetes: a position statement by the American Diabetes Association. Diabetes Care 2018;41:2648–68.

9. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–97.

10. Kleber M, Lass N, Papcke S, Wabitsch M, Reinehr T. One-year follow-up of untreated obese white children and adolescents with impaired glucose tolerance: high conversion rate to normal glucose tolerance. Diabet Med 2010;27:516–21.

11. Weiss R, Taksali SE, Tamborlane WV, Burgert TS, Savoye M, Caprio S. Predictors of changes in glucose tolerance status in obese youth. Diabetes Care 2005;28:902–9.

12. Gallardo TV, Avila AA, Unuane MN, Codner E. Fasting glucose versus oral glucose tolerance test for detection of glucose intolerance in obese children. Rev Med Chil 2006;134:1146–52.

13. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1327–34.

14. Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, et al. Clinical care guidelines for cystic fibrosisrelated diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 2010;33:2697–708.

15. Brooks AP, Metcalfe J, Day JL, Edwards MS. Iron deficiency and glycosylated haemoglobin A. Lancet 1980;2:141.

16. Unnikrishnan R, Anjana RM, Mohan V. Drugs affecting HbA1c levels. Indian J Endocrinol Metab 2012;16:528–31.

17. Lacy ME, Wellenius GA, Sumner AE, Correa A, Carnethon MR, Liem RI, et al. Association of sickle cell trait with hemoglobin A1c in African Americans. JAMA 2017;317:507–15.

18. Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, et al. Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care 2008;31:1991–6.

19. Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, et al. Utility of hemoglobin A(1c) for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care 2011;34:1306–11.

20. Buse JB, Kaufman FR, Linder B, Hirst K, El Ghormli L, Willi S, et al. Diabetes screening with hemoglobin A(1c) versus fasting plasma glucose in a multiethnic middle-school cohort. Diabetes Care 2013;36:429–35.

21. Lee JM, Wu EL, Tarini B, Herman WH, Yoon E. Diagnosis of diabetes using hemoglobin A1c: should recommendations in adults be extrapolated to adolescents? J Pediatr 2011;158:947. –52. e1-3.

22. Yang C, Ding Z, Zhou H, Chen D, Huang Z, Yang C, et al. Prevalence of prediabetes by the fasting plasma glucose and HbA1c screening criteria among the children and adolescents of Shenzhen, China. J Diabetes 2018;Jul 4 [Epub]. https://doi.org/10.1111/1753-0407.12820.

23. Al Amiri E, Abdullatif M, Abdulle A, Al Bitar N, Afandi EZ, Parish M, et al. The prevalence, risk factors, and screening measure for prediabetes and diabetes among Emirati overweight/obese children and adolescents. BMC Public Health 2015;15:1298.

24. Nam HK, Cho WK, Kim JH, Rhie YJ, Chung S, Lee KH, et al. HbA1c cutoff for prediabetes and diabetes based on oral glucose tolerance test in obese children and adolescents. J Korean Med Sci 2018;33:e93.

25. Khokhar A, Naraparaju G, Friedman M, Perez-Colon S, Umpaichitra V, Chin VL. Comparison of A1C to oral glucose tolerance test for the diagnosis of prediabetes in overweight and obese youth. Clin Diabetes 2017;35:133–40.

26. Ehehalt S, Wiegand S, Körner A, Schweizer R, Liesenkötter KP, Partsch CJ, et al. Low association between fasting and OGTT stimulated glucose levels with HbA1c in overweight children and adolescents. Pediatr Diabetes 2017;18:734–41.

27. Yoon JS, So CH, Lee HS, Hwang JS. Glycated hemoglobin A1c as a screening test for detecting type 2 diabetes mellitus in obese children and adolescents. J Pediatr Endocrinol Metab 2018;31:503–6.

28. Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, et al. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care 2011;34:960–7.

29. Chan CL, Pyle L, Newnes L, Nadeau KJ, Zeitler PS, Kelsey MM. Continuous glucose monitoring and its relationship to hemoglobin A1c and oral glucose tolerance testing in obese and prediabetic youth. J Clin Endocrinol Metab 2015;100:902–10.

30. Bergman M, Manco M, Sesti G, Dankner R, Pareek M, Jagannathan R, et al. Petition to replace current OGTT criteria for diagnosing prediabetes with the 1-hour postload plasma glucose ≥ 155 mg/dl (8.6 mmol/L). Diabetes Res Clin Pract 2018;146:18–33.

31. Jagannathan R, Sevick MA, Fink D, Dankner R, Chetrit A, Roth J, et al. The 1-hour post-load glucose level is more effective than HbA1c for screening dysglycemia. Acta Diabetol 2016;53:543–50.

32. Abdul-Ghani MA, Abdul-Ghani T, Müller G, Bergmann A, Fischer S, Bornstein S, et al. Role of glycated hemoglobin in the prediction of future risk of T2DM. J Clin Endocrinol Metab 2011;96:2596–600.

33. Kasturi K, Onuzuruike AU, Kunnam S, Shomaker LB, Yanovski JA, Chung ST. Two- vs one-hour glucose tolerance testing: predicting prediabetes in adolescent girls with obesity. Pediatr Diabetes 2019;20:154–9.